Fosun Pharma forms partnership for healthcare investment fund

Shanghai Fosun Pharmaceutical (HKEX: 2196) has announced that its subsidiary, Fosun Pingyao, entered into a partnership agreement on April 25, 2025, with Shanghai Fujian, Fosun High Tech, and Fuyao Zhigang to jointly form Henan Fujian Xingweilai Health Investment Partnership (Limited Partnership). The total capital contribution for Henan Fujian will be RMB10.00 million, with Fosun Pingyao contributing RMB4.90 million as a Limited Partner. Fosun High Tech will contribute RMB2.90 million, Shanghai Fujian RMB0.10 million and Fuyao Zhigang RMB2.10 million. Fosun High Tech's involvement designates the transaction as a connected one under Hong Kong Listing Rules, subject to reporting and announcement requirements. The partnership aims to invest in medical devices, diagnostics, life sciences, and innovative drugs. The relevant contribution will be financed by the self-raised funds of Fosun Pingyao.